- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01473862
Adolescent Loss: The Impact of Loss on Adolescent Oncology Patients (ALOSS)
Study Overview
Status
Conditions
Detailed Description
All participants will asked to complete a bereavement questionnaire quantifying the losses they have experienced. All participants will be screened for depression/anxiety as well as life outlook using validated tools. Patients who identify that they have experienced the loss of someone significant in their life on the bereavement questionnaire will continue with the study and complete a battery of validated psychological inventories. They will be asked to identify their most significant loss in regards to completion of the remainder of the questionnaire. In addition, those who identify losing a friend to cancer will be invited to participate in a 30-45 minute semi-structured interview (in person or via telephone) during a second session with the study staff. This interview will be audiotaped, to allow for transcription and analysis later. Parents will complete demographic information, the bereavement questionnaire, and complete inventories of family coping / cohesion regardless of child's responses to bereavement questionnaire.
In addition, those who identify losing a friend to cancer will be invited to participate in a 30-45 minute semi-structured interview (in person or via telephone) during a second session with the study staff.
Primary Objectives:
- Estimate the prevalence of loss, with particular interest in the extent of peer loss, in adolescent oncology patients who have been on therapy ≥ 12 months (≥ 6 months if progressive or refractory disease) or off therapy for ≤ 3 years.
- Describe the impact of loss on adolescent oncology patients by focusing on coping efficacy, psychological distress, meaning-making, and complicated bereavement.
Secondary Objective:
- Describe parental knowledge of losses experienced by an adolescent child who has recently undergone therapy.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 13-21 inclusive at time of study enrollment
- English speaking
- Research participant carries a diagnosis of a malignancy (or serious non-malignant disorder requiring HSCT) >12 months.
- Research participant carries a diagnosis of a malignancy (or serious non-malignant disorder requiring HSCT) for >6 months and <12 months but has evidence of refractory/progressive disease.
- Patients who have completed cancer-directed therapy >36 months ago are not eligible. (Note: Allogenic transplant recipients will be considered "off-therapy" 1 year after HSCT.)
- No known history of significant cognitive deficits (i.e. with major impairments) that would preclude completion of study measures; not meant to exclude research participants with mild learning problems.
- Research participant and 1 parent willing to participate and provide consent/assent according to institutional guidelines. Parent may decline to participate in parental inventories, but consent to adolescent participation.
Exclusion Criteria:
- Less than 13-years of age at completion of therapy.
- Patients on hospice who are without scheduled follow-up at St. Jude Children's Research Hospital (SJCRH)
- "Observation" patients. Patients that are being followed by imaging due to previous identification of an atypical lesion on radiographic imaging not identified to have a specific diagnosis.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants who have experienced the death of a friend or relative by type of loss.
Time Frame: Once on Day 1
|
The prevalence of loss among the participants will be calculated.
The type of losses will be described.
|
Once on Day 1
|
|
Descriptive statistics of coping efficacy scores, psychological distress scores, meaning-making scores, and complicated bereavement scores.
Time Frame: Once on Day 1
|
All data for this objective will be mainly analyzed in a descriptive manner.
The score for coping efficacy will be calculated from the General Coping Efficacy instrument.
In addition, a subset of participants who identify losing a friend to cancer will be invited to complete a 30-45 minute semi-structured interview.
|
Once on Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of parents with knowledge of losses experienced by adolescent child.
Time Frame: Once on Day 1
|
Descriptive analysis from the Bereavement Questionnaire (parent version).
|
Once on Day 1
|
Collaborators and Investigators
Investigators
- Principal Investigator: Liza Johnson, MD,MPH, St. Jude Children's Research Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XPD11-150 ALOSS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adolescent Oncology Patients
-
Stanford UniversityActive, not recruitingPediatric Cancer | Oncology | Adolescent BehaviorUnited States
-
Saglik Bilimleri UniversitesiCompleted
-
AmMax Bio, Inc.CompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
Centre Francois BaclesseRecruitingSurgery | Elderly Patients | OncologyFrance
-
Tel-Aviv Sourasky Medical CenterUnknownCephalic Phase, Oncology PatientsIsrael
-
Damanhour UniversityCompletedOncology Patients | Relaxation ProgramEgypt
-
Charles KamenNational Cancer Institute (NCI); Wayne State UniversityRecruitingCaregivers | Oncology Patients | Cancer SupportUnited States
-
Brigham and Women's HospitalGordon and Betty Moore FoundationCompletedMedical Intensive Care Unit (MICU) Patients | Oncology Unit PatientsUnited States